Active LSD

GPTKB entity

Statements (65)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:abbreviation LSD
gptkbp:abusePotential Low
gptkbp:allows Develops rapidly
Diminishes after a few days
gptkbp:CASNumber 50-37-3
gptkbp:chemicalClass gptkb:Ergoline
gptkb:Lysergamide
gptkbp:color Colorless
gptkbp:countryOfOrigin gptkb:Switzerland
gptkbp:discoveredBy gptkb:Albert_Hofmann
gptkbp:discoveredIn 1938
gptkbp:duration 8-12 hours
gptkbp:effect gptkb:Euphoria
gptkb:Synesthesia
gptkb:Hallucinations
Altered perception
Spiritual experiences
gptkbp:excretion Kidney
gptkbp:firstSynthesized 1938
gptkbp:firstTestMatch 1943
gptkbp:form gptkb:tablet
gptkb:water
gptkb:Blotter_paper
Gelatin
gptkbp:fullName gptkb:Lysergic_acid_diethylamide
gptkbp:hasMolecularFormula C20H25N3O
https://www.w3.org/2000/01/rdf-schema#label Active LSD
gptkbp:IUPACName (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
gptkbp:legalStatus gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
gptkbp:mainStreet gptkb:Acid
gptkb:Lucy
gptkb:Blotter
Tabs
gptkbp:mechanismOfAction 5-HT2A receptor agonist
Serotonergic psychedelic
gptkbp:metabolism Liver
gptkbp:molecularWeight 323.43 g/mol
gptkbp:notableEvent First intentional ingestion by Albert Hofmann on April 19, 1943 (Bicycle Day)
gptkbp:origin Derived from ergot fungus
gptkbp:overdoseSymptoms No known lethal dose in humans
Very low toxicity
gptkbp:producedBy Sandoz Laboratories (historically)
gptkbp:PubChem_CID 5761
CHEMBL27
gptkbp:routeOfAdministration gptkb:Oral
Intravenous
Sublingual
gptkbp:sideEffect gptkb:Nausea
gptkb:Anxiety
gptkb:Flashbacks
gptkb:Paranoia
Increased heart rate
Dilated pupils
gptkbp:solubility Ethanol-soluble
Water-soluble
gptkbp:UNII D839GV0YJ7
gptkbp:usedFor gptkb:Psychedelic_therapy_(historically)
Recreational purposes
gptkbp:usedIn gptkb:MKUltra_experiments
gptkb:Counterculture_movement_of_the_1960s
gptkbp:bfsParent gptkb:R34
gptkbp:bfsLayer 6